A detailed history of Lsv Asset Management transactions in Exelixis, Inc. stock. As of the latest transaction made, Lsv Asset Management holds 5,763,728 shares of EXEL stock, worth $155 Million. This represents 0.28% of its overall portfolio holdings.

Number of Shares
5,763,728
Previous 2,774,707 107.72%
Holding current value
$155 Million
Previous $65.8 Million 96.69%
% of portfolio
0.28%
Previous 0.14%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 06, 2024

BUY
$20.34 - $23.73 $60.8 Million - $70.9 Million
2,989,021 Added 107.72%
5,763,728 $130 Million
Q1 2024

May 06, 2024

BUY
$20.17 - $23.93 $52.8 Million - $62.6 Million
2,616,278 Added 1651.39%
2,774,707 $65.8 Million
Q4 2023

Feb 06, 2024

SELL
$19.25 - $24.13 $16.9 Million - $21.2 Million
-879,211 Reduced 84.73%
158,429 $3.8 Million
Q3 2023

Nov 03, 2023

SELL
$19.04 - $22.74 $4.38 Million - $5.23 Million
-229,835 Reduced 18.13%
1,037,640 $22.7 Million
Q2 2023

Aug 02, 2023

SELL
$18.17 - $20.48 $15.2 Million - $17.2 Million
-838,909 Reduced 39.83%
1,267,475 $24.2 Million
Q1 2023

May 02, 2023

SELL
$16.3 - $19.41 $6.62 Million - $7.89 Million
-406,299 Reduced 16.17%
2,106,384 $40.9 Million
Q4 2022

Feb 08, 2023

BUY
$14.96 - $17.39 $7.14 Million - $8.31 Million
477,585 Added 23.47%
2,512,683 $40.3 Million
Q3 2022

Nov 07, 2022

BUY
$15.68 - $22.27 $3.78 Million - $5.37 Million
241,137 Added 13.44%
2,035,098 $31.9 Million
Q2 2022

Aug 10, 2022

BUY
$17.44 - $23.16 $21.4 Million - $28.4 Million
1,226,172 Added 215.96%
1,793,961 $37.4 Million
Q1 2022

May 12, 2022

BUY
$17.03 - $22.67 $9.67 Million - $12.9 Million
567,789 New
567,789 $12.9 Million
Q4 2020

Feb 08, 2021

SELL
$18.39 - $24.8 $1.4 Million - $1.89 Million
-76,200 Closed
0 $0
Q4 2019

Feb 10, 2020

BUY
$15.15 - $18.89 $1.15 Million - $1.44 Million
76,200 New
76,200 $1.34 Million

Others Institutions Holding EXEL

About EXELIXIS, INC.


  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $8.63B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track Lsv Asset Management Portfolio

Follow Lsv Asset Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lsv Asset Management, based on Form 13F filings with the SEC.

News

Stay updated on Lsv Asset Management with notifications on news.